BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report)’s stock price was down 4% during trading on Friday . The company traded as low as C$4.26 and last traded at C$4.31. Approximately 14,972 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 23,139 shares. The stock had previously closed at C$4.49.
BriaCell Therapeutics Price Performance
The stock has a market cap of C$31.25 million, a price-to-earnings ratio of -0.30 and a beta of 2.06. The stock’s 50-day moving average is C$5.38 and its 200 day moving average is C$7.59.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.
Read More
- Five stocks we like better than BriaCell Therapeutics
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
